OGN icon

Organon & Co

8.40 USD
-0.03
0.36%
Updated May 22, 11:49 AM EDT
1 day
-0.36%
5 days
-5.72%
1 month
-25.27%
3 months
-44.30%
6 months
-45.03%
Year to date
-43.85%
1 year
-61.75%
5 years
-74.74%
10 years
-74.74%
 

About: Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Employees: 10,000

0
Funds holding %
of 7,245 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

25% more call options, than puts

Call options by funds: $31.7M | Put options by funds: $25.4M

1% less repeat investments, than reductions

Existing positions increased: 217 | Existing positions reduced: 220

2% less capital invested

Capital invested by funds: $3.07B [Q4 2024] → $3.01B (-$63M) [Q1 2025]

8% less first-time investments, than exits

New positions opened: 85 | Existing positions closed: 92

1.7% less ownership

Funds ownership: 79.8% [Q4 2024] → 78.1% (-1.7%) [Q1 2025]

4% less funds holding

Funds holding: 717 [Q4 2024] → 691 (-26) [Q1 2025]

20% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 4 (-1) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$10
19%
upside
Avg. target
$14
67%
upside
High target
$18
114%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Piper Sandler
David Amsellem
114%upside
$18
Overweight
Maintained
15 May 2025
Morgan Stanley
Terence Flynn
19%upside
$10
Equal-Weight
Maintained
5 May 2025

Financial journalist opinion

Based on 59 articles about OGN published over the past 30 days

Neutral
Accesswire
14 hours ago
Protect Your Investment: Contact Levi & Korsinsky About the Organon & Co. (OGN) Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
Protect Your Investment: Contact Levi & Korsinsky About the Organon & Co. (OGN) Investigation
Neutral
Accesswire
1 day ago
OGN ACTIVE INVESTIGATION: Lost Money on Organon & Co.? Contact Levi & Korsinsky Now
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
OGN ACTIVE INVESTIGATION: Lost Money on Organon & Co.? Contact Levi & Korsinsky Now
Neutral
Accesswire
1 day ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Shareholders to Connect
Neutral
Accesswire
2 days ago
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Organon & Co. (OGN)
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Organon & Co. (OGN)
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Organon & Co. (OGN) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Organon & Co. (OGN) And Encourages Shareholders to Reach Out
Neutral
Accesswire
2 days ago
Protect Your Investment: Contact Levi & Korsinsky About the Organon & Co. (OGN) Investigation
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
Protect Your Investment: Contact Levi & Korsinsky About the Organon & Co. (OGN) Investigation
Neutral
PRNewsWire
2 days ago
OGN INVESTIGATION: Investigation Launched into Organon & Co. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Firm
SAN DIEGO , May 20, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon as well as certain of its executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-organon-co-investigation-ogn.html You can also contact attorneys J.C.
OGN INVESTIGATION: Investigation Launched into Organon & Co. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Firm
Neutral
Accesswire
3 days ago
Did Organon & Co. (OGN) Mislead Investors? Levi & Korsinsky Investigates
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
Did Organon & Co. (OGN) Mislead Investors? Levi & Korsinsky Investigates
Neutral
Accesswire
3 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Shareholders to Learn More About the Investigation
Neutral
Accesswire
3 days ago
Ongoing Investigation into Organon & Co. (OGN): Contact Levi & Korsinsky About Potential Fraud
NEW YORK, NY / ACCESS Newswire / May 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B.
Ongoing Investigation into Organon & Co. (OGN): Contact Levi & Korsinsky About Potential Fraud
Charts implemented using Lightweight Charts™